“…Empowered by advances in experimental methodologies (Mazor et al, 2012; Cantor et al, 2011; Harding et al, 2010), epitope prediction tools (Wang et al, 2010; Bryson et al, 2010; Jawa et al, 2013), and protein design algorithms (Parker et al, 2013; Choi et al, 2013, King et al, 2014), T cell epitope deletion is being applied to a progressively larger number of therapeutic candidates. Early clinical data from epitope depleted biotherapeutics suggests that molecular engineering has had the desired effect in human patients (Morris et al, 2005; Entwistle et al, 2012), although to date there is no comparative clinical data for T cell epitope depleted and wild type versions of the same biotherapeutic. Deimmunized variants of Pseudomonas exotoxin should soon be entering clinical trials (Mazor et al, 2014), and comparison to results with the wild type immunotoxin SS1P (Kreitman et al, 2009) will provide new insights into the clinical utility of T cell epitope deletion.…”